Home
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Dr Reddy’s Settles US Patent Litigation With Intercept On Ocaliva
Five Further Firms Have Filed For Generic Obeticholic Acid
Sep 01 2022
•
By
Chloe Kent
The ruling states that Dr. Reddy's will not be able to market its generic until 2035 • Source: Shutterstock
More from Legal & IP
More from Generics Bulletin